Virtual Library

Start Your Search

Naoya Ozawa



Author of

  • +

    P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.01-34 - Short Hydration Regimen with a Modified Dose of Magnesium Supplementation for Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy (ID 12290)

      12:00 - 13:30  |  Author(s): Naoya Ozawa

      • Abstract

      Background

      Intravenous administration of magnesium is recommended for patients receiving high-dose cisplatin with a short hydration regimen in terms of protection against cisplatin-induced nephrotoxicity. However, the optimal dose of the magnesium supplementation has not been clarified. The aim of this trial was to investigate the safety and efficacy of short hydration regimen with 20mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      The key eligibility criteria included cytologically or histologically proven lung cancer, candidates for cisplatin (≥60 mg/m2) based chemotherapy or chemoradiotherapy, no prior chemotherapy, age ranged 20 and 75 years old and adequate renal function. Cisplatin was administered with pre-hydration containing 20 mEq of magnesium sulfate. Mannitol was administered just before the cisplatin infusion as an enforced diuresis. The primary endpoint was the proportion of patients without a Grade 2 or higher elevation in creatinine. The study was registered at UMIN-CTR as UMIN000011687.

      4c3880bb027f159e801041b1021e88e8 Result

      Forty patients with a median age of 66 years (range, 35-74) were enrolled in the study. Of these, 16 had adenocarcinoma, 12 had squamous cell carcinoma, 5 had small cell carcinoma, 2 had large cell carcinoma and 5 had other histology. The median baseline creatinine value was 0.71 mg/dl. The median dose of cisplatin at the first cycle was 80 mg/m2. Twenty-nine patients received cisplatin and vinorelbine as their most frequent regimen and 24 patients received 4 cycles of chemotherapy. In the first cycle, no patients developed Grade 2 creatinine toxicity. During the whole treatment period, one patient developed Grade 2 creatinine elevation, and thus, the proportion of patients without a Grade 2 or higher elevation in creatinine was 97.5% (95%CI 86.8‐99.9). Grade 1 hypermagnesemia was observed in 3 patients.

      8eea62084ca7e541d918e823422bd82e Conclusion

      This study indicates short hydration regimen with 20mEq of magnesium supplementation was safe and feasible for lung cancer patients receiving cisplatin-based chemotherapy without risk of severe nephrotoxicity.

      6f8b794f3246b0c1e1780bb4d4d5dc53